Abstract. Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Replication factor C (RFC) plays an important role in DNA replication and checkpoint control during the cell cycle. RFC is comprised of one large subunit [replication factor C, subunit 1 (RFC1)] and four small subunits [replication factor C, subunits 2-5 (RFC2-5)]. The role of RFC3 in the development of HCC is, as of yet, not fully understood. In the present study, western blot analysis and reverse-transcriptionquantitative PCR were used to measure the expression levels of replication factor C, subunit 3 (RFC3) in HCC tissues and HCC cells. Lentivirus-mediated RFC3-specific short hairpin RNA (shRNA) was used to knock down the expression of RFC3 in HCC cells in order to examine the effects of RFC3 on HCC cell proliferation and growth. Furthermore, the expression levels of cell cycle-related proteins were also measured in the HCC cells in which RFC3 was knocked down. Our results revealed that the expression level of RFC3 was markedly upregulated in the HCC tissues and cells. In addition, MTS and cell growth assays were used to determine the viability and proliferation of the HCC cells in which RFC3 was knocked down, and the results revealed that both cell viability and proliferation were effectively suppressed. The downregulation of RFC3 expression led to HCC cell cycle arrest in the S phase, partly by regulating the epression of cell cycle-related proteins, such as p21, p53, p57 and cyclin A. The results of the present study suggest that RFC3 plays an important role in the development of HCC, and may thus be a potential biological target in the treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide (1, 2) . An estimated 350,000 deaths from liver cancer occur worldwide each year (3) . The highest liver cancer rates are to be found in East and Southeast Asia, and in Central and Western Africa; chronic hepatitis B virus (HBV) and C (HCV) infection are responsbile for approximately 75-80% of the HCC cases worldwide, particularly in Asian and African populations (4, 5) .
The fidelity of DNA replication is generally considered an important characteristic of cancer progression and during the cell cycle. Dysfunctional DNA damage repair and checkpoints during the cell cycle process contribute to genomic instability. Replication factor C (RFC) is a heteropentameric primer-recognition protein complex involved in DNA replication, DNA damage repair and checkpoint control during cell cycle progression (6) (7) (8) (9) (10) . The RFC complex functions to load proliferating cell nuclear antigen (PCNA), a ring-shaped homotrimer, onto DNA in an ATP-dependent manner in order to provide a sliding clamp for various proteins involved in DNA replication processes (11) .
RFC is comprised of one large subunit [replication factor C, subunit 1 (RFC1)] and four small subunits [replication factor C, subunits 2-5 (RFC2-5)]. Of these subunits, replication factor C, subunit 3 (RFC3), a 38-kDa subunit, has been reported to be overexpressed in esophageal adenocarcinomas and ovarian carcinomas (12, 13) . Moreover, RFC3 knockdown has been shown to result in the inhibition of cancer cell proliferation and growth (12, 14) . The disruption of the RFC3-PCNA complex induced by 9-cis retinoic acid-activated retinoid X receptor α (RXRα) has been shown to inhibit the growth of cancer and embryonic cells and to arrest S phase entry (15) . These findings suggest that RFC3 may be one of the most important cancer antigens. However, its role in the development of HCC remains unclear.
In this study, we found that RFC3 was overexpressed in HCC tissues and cells. Further investigations revealed that RFC3 is a critical factor in promoting the development of HCC, as the silencing of RFC3 by shRNA led to cell cycle arrest. Our data provide new insight into the role of RFC3 in the development of HCC.
Materials and methods
Tissue samples. Liver tumor tissue samples were obtained from 24 patients (age: mean 55, rage 40-68, gender: female 5, male 19) who were diagnosed with HCC at the Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China in 2012. A total of 24 human HCC tissues and 12 adjacent non-tumor tissue samples were examined in this study. For each case, tumor samples with matched adjacent non-tumor tissue samples were collected during surgical resection and frozen in liquid nitrogen and stored at -80˚C. This study was approved by the Ethics Committee of Sun Yat-Sen University and all patients provided written informed consent prior to obtaining the samples.
Cell lines and culture. In this study, we used 1 human hepatocyte cell line (L02) and 5 HCC cell lines (HepG2, BEL-7402, Hep3B, SMMC-7721 and LM3), obtained from Shanghai Cell Bank (Chinese Academy of Science), to detect RFC3 expression. The cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Gibco BRL, Paisley, Scotland, UK) supplemented with 10% fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2% L-glutamine (all from Biological Industries Israel Beit-Haemek Ltd. Kibbutz Beit-Haemek, Israel) at 37˚C in an atmosphere with 5% CO 2 .
RNA isolation and RT-qPCR. Total RNA was extracted from the tissues and cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the instructions provided by the manufacturer. Reverse transcription was performed using a reverse transcription kit (Takara Bio, Dalian, China), and primers were designed as follows: RFC3 forward, 5'-GCC TGCAGAGTGCAACAATA-3' and reverse, 5'-TCAAGG AGCCTTTGTGGAGT-3'; and GAPDH forward, 5'-GAGT CAACGGATTTGGTCGT-3' and reverse, 5'-GACAAGCTT CCCGTTCTCAG-3'. Amplification reactions were performed in a 20 µl volume of SYBR-Green PCR Master mix (from Takara Bio). All the reactions were performed in triplicate in a LightCycler Real-Time PCR system. The RFC3 mRNA expression levels were standardized to the GAPDH mRNA levels using the comparative Ct method. All experiments were performed at least 3 times.
Immunohistochemistry (IHC)
. IHC was performed as previously described (16) . Briefly, the tumor sections were deparaffinized using xylene and rehydrated with graded ethyl alcohol, and a solution of 3% (v/v) H 2 O 2 was then added to halt the peroxidase activity. Antigen retrieval was performed by heating the tumor sections in 10 mM sodium citrate buffer (pH 6.0) at 95-100˚C for 20 min. After being washed 3 times with phosphatebuffered saline (PBS; Sigma-Aldrich, St. Louis, MO, USA), the sections were blocked with 3% bovine serum albumin (BSA; Sigma-Aldrich) at room temperature for 1 h, and this was followed by overnight incubation at 4˚C with RFC3 antibody (sc-390293; 1:100 dilution; Santa Cruz Biotechnology, Inc., CA, USA). After being washed 3 times with PBS, the sections were incubated at 37˚C for 2 h with secondary antibodies. Finally, the sections were counterstained with hematoxylin.
Western blot analysis. The cells were harvested and then lysed in radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate, 1 mM EDTA and 1 mM NaF], containing protease inhibitor cocktail (Sigma-Aldrich). The cell lysates were boiled for 5 min and refrigerated on ice, and this was followed by centrifugation at 10,000 x g for 30 sec. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred onto polyvinylidene fluoride (PVDF) membranes. The membranes were blocked in 5% non-fat dry milk and then probed with the primary antibodies against RFC3 (sc-390293; 1:500 dilution; Santa Cruz Biotechnology, Inc.) and p53 (ab31333; 1:500 dilution), p21 (ab7960; 1:200 dilution), p57 (ab75974; 1:500 dilution), cyclin A (ab137769; 1:1,000 dilution) and cyclin B1 (ab32053; 1:3,000 dilution) (all from Abcam, Cambridge, MA, USA). Subsequently, the membranes were washed twice with TBST and incubated with horseradish peroxidase-conjugated AffiniPure goat anti-mouse IgG (H+L) (115-035-003; 1:5,000 dilution) or goat anti-rabbit IgG (H+L) (111-035-003; 1:5,000 dilution; both from Jackson ImmunoResearch, West Grove, PA, USA) secondary antibodies at room temperature for 1 h. The membranes were washed another 3 times and then visualized using an ECL kit (Forevergen Biosciences Co., Ltd., Guangzhou, China).
Construction of shRFC3 lentivirus and gene silencing.
The lentiviral vector, LV-008 (Forevergen Biosciences Co., Ltd.), expressing short hairpin RNA (shRNA) and containing the green fluorescent protein (GFP) gene was used as a reporter. The recombinant lentiviruses were designed to generate shRNA targeting the sequence of the RFC3 gene (5'-AAGTAACTACCACCTTGAAGTTA-3') and negative control (NC) (5'-TGGTTTACATGTCGACTAA-3'). The LV-008-shRFC3 plasmids were transfected into 293T cells (Shanghai Cell Bank, Chinese Academy of Science), together with the lentiviral packaging vectors, to generate the respective lentiviruses. Infection lentiviruses were collected at 72 h post-transfection, and the lentiviruses were concentrated by ultracentrifugation for 1.5 h at 25,000 rpm in an SW28 rotor (Bekcman Instruments Inc., Fullerton, CA, USA). For lentiviral infection, the SMMC-7721 cells were seeded in a 6-well plate at a density of 50,000 cells/well and infected with the lentiviruses in the presence of 5-10 µg/ml of polybrene. The cells in which RFC3 was knocked down were screened out with 2 µg/ml puromycin for 10-15 days. The knockdown efficiency was validated by RT-qPCR and western blot analysis on day 5 post-infection. Each experiment was performed in triplicate.
Colony formation assay. The cells were digested at the logarithmic growth phase and seeded into 6-well plates at density gradients of 50, 100 and 200 cells/well. Following 2 weeks of culture, the cells were washed and fixed with 4% paraformaldehyde for 30 min at room temperature, and then stained with crystal violet. The number of colonies was counted under a fluorescence microscope (BX-50; Olympus, Tokyo, Japan). Each experiment was performed in triplicate.
3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) viability assay.
The viability of the cells was determiend by MTS assay (Sigma-Aldrich, St. Louis, MO, USA). Cells in the logarithmic growth phase were collected and seeded at a density of 1x10 3 cells/well in 96-well plates, in triplicate. On days 1, 2, 3 and 4, MTS reagent was added to the cells at a ratio of 1:10 followed by incubation at 37˚C for 4 h. The solution was removed, and the cells were dissolved with dimethyl sulfoxide (Sigma-Aldrich). The absorbance of each well was measured using an LW R96 ELISA microplate reader (Diatek, West Bengal, India) at a wavelength of 490 nm. Each experiment was performed in triplicate.
Cell growth curves. The cells were digested, and the number of living cells was counted using the method described by Freshney (17) . The cells were then seeded in 3 wells of a 12-well plate at approximately 1x10 5 cells/well. The living cells were digested and counted on days 1, 2 and 3. The experiments were repeated 3 times, and averages were used to plot the cell growth curves.
Flow cytometric analysis. The cells were harvested and washed in PBS, and fixed in ice-cold 70% ethanol for 1 h. Following treatment with RNase A (50 µg/ml; Sigma-Aldrich), the cells were stained with propidium iodide (PI; Sigma-Aldrich) for 30 min at room temperature and then analyzed and recorded using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA). Cell cycle analysis was performed using FlowJo software (TreeStar Inc., Ashland, OR, USA).
Statistical analysis. SPSS 18.0 statistical software was used for statistical analysis. Data are presented as the means ± SD, and all experiments were performed in triplicate (n=3). Statistical analysis was performed using analysis of variance (ANOVA). A P-value <0.05 was considered to indicate a statistically significant difference.
Results

RFC3 is overexpressed in human liver tumor tissue.
It has previously been reported that RFC3 has oncogenic activity and is overexpressed in epithelial carcinomas (12, 13) . In this study, in order to determine whether the overexpression of RFC3 is associated with the development of HCC, liver tumor tissue samples from 24 patients were examined by RT-qPCR using RFC3-specific primers. Paired adjacent normal tissue samples were used as the controls. As shown in Fig. 1A , the mRNA expression level of RFC3 in tumor tissue samples was markedly upregulated compared with the adjacent non-tumor tissues. Moreover, IHC analysis revealed that strong positive staining in the liver tumor tissues, indicating the overexpression of RFC3 protein (Fig. 1B ; compare 'Tumor' to 'Normal'). Taken together, these results indicated that RFC3 was upregulated in the liver tumor tissues.
RFC3 is overexpressed in HCC cell lines.
To further confirm the stimulatory effect of RFC3 on HCC, we sought to identify an RFC3-sensitive cell line. For this purpose, 5 HCC cell lines (HepG2, BEL-7402, Hep3B, SMMC-7721 and LM3) were used to measure the mRNA and protein expression of RFC3 by RT-qPCR and western blot analysis, respectively. A normal hepatocyte cell line (L02) was used as the negative control. In brief, we found that both the mRNA and protein levels of RFC3 were increased in all HCC cell lines compared to the hepatocyte cell line, further confirming that RFC3 overexpression is associated with HCC (Fig. 2) . Of the HCC cell lines, the SMMC-7721 cells exhibited the highest mRNA and protein expression of RFC3 and were thus used in subsequent experiments.
Downregulation of RFC3 through lentivirus-mediated shRNA in the SMMC-7721 cell line.
To examine the role RFC3 plays in HCC, a stable HCC cell line in which RFC3 was knocked down was established using lentivirus-mediated RNA interference (RNAi) technology. The SMMC-7721 cell line was selected to establish the HCC cell line in which RFC3 would be knocked down. The knockdown effect was evaluated by RT-qPCR and western blot analysis. As shown in Fig. 3A , RFC3 mRNA expression was reduced by approximately 70% in the SMMC-7721-shRFC3 cells compared to the NC cells (P<0.01). Western blot analysis further confirmed that almost 90% of RFC3 expression was markedly suppressed in the SMMC-7721-shRFC3 cells (Fig. 3B and C) .
Knockdown of RFC3 inhibits HCC cell proliferation and viability.
We sought to examine the effects of RFC3 knockdown on HCC cells. To this end, we examined the proliferation and viability of SMMC-7721-shRFC3 cells using a cell colony formation assay, MTS viability assay and cell growth curve assay, respectively. As shown in Fig. 4A , statistical analysis indicated that the colony-forming ability of the SMMC-7721-shRFC3 cells decreased to 62% (P<0.01) compared with that of the NC cells which was 97%. Moreover, a marked decrease in cellular viability was observed in the cells in which RFC3 was knocked down (SMMC-7721-shRFC3 cells). Furthermore, the cell growth curve assay revealed that the population of SMMC-7721-shRFC3 living cells was considerably lower compared with the NC cells (Fig. 4C) . Collectively, these data indicated that the knockdown of RFC3 inhibited HCC cell proliferation and viability.
Knockdown of RFC3 induces HCC cell cycle arrest at the S phase.
As abnormal cell proliferation is closely associated with the dysregulation of the cell cycle (18), we examined whether the knockdown of RFC3 affects the HCC cell cycle using flow cytometric analysis. As shown in Fig. 5A and B, the knockdown of RFC3 significantly increased the percentage of cells in the S phase, but decreased that in the G0/G1 phase; moreover, the downregulation of RFC3 did not significantly alter the percentage of cells in the G2/M phase, indicating that the cell cycle was arrested at the S phase, when RFC3 was knocked down.
To further elucidate the mechanisms behind the cell cycle arrest at the S phase following the knockdown of RFC3, we measured the expression levels of cell cycle-related proteins by western blot analysis. As shown in Fig. 5C , in the HCC cells in which RFC3 was knocked down, the tumor suppressor genes, p53, p21 and p57 were all upregulated. In the cell cycle, p21 functions as a negative regulator that inhibits DNA synthesis and arrests the cell cycle at the G1/S phase by binding to and inhibiting the activity of cyclin-dependent kinase (CDK)2, CDK1, CDK4 and CDK6 complexes (19) . p53 upregulates the expression of p21 (20) . p57 is also a tight-binding inhibitor of CDK2, CDK4 and CDK6 complexes and a negative regulator of cell proliferation (21) . Based on this information, our data indicated that RFC3 knockdown upregulated p53 expression, subsequently inducing the upregulation of p21, and eventually inhibiting the cell cycle. Similarly, the knockdown of RFC3 upregulated p57 and directly resulted in the blocking of CDK complex activity. Indeed, the expression of cyclin A, a known cell cycle protein which is associated with the CDK2 complex required for G1-S phase transition (22) , was downregulated (Fig. 5C ). Of note, the expression of cyclin B1, a protein required for G2-M phase transition (23), was not markedly affected (Fig. 5C) , suggesting that the knockdown of RFC3 specifically regulates G1-S phase transition. Taken together, these findings demonstrate that the knockdown of RFC3 induces HCC cell cycle arrest at the S phase by regulating tumor suppressor genes involved in G1-S phase transition.
Discussion
HCC is one of the most common and lethal malignancies in the world (1, 2) . The identification of novel therapeutic targets that will contribute to the development and progression of HCC is obviously desirable if we are to combat this lethal disease. RFC3 is clearly one of the most important cancer antigens since it plays an indispensable role in DNA replication (7, 8, 24, 25) . Previous studies have shown that the overexpression of RFC3 is closely related to esophageal adenocarcinomas and ovarian carcinomas, implying that this gene plays a role in tumor development (12, 13) ; however, its role in the development of HCC remains unclear.
In the present study, we aimed to investigate the expression and biological functions of RFC3 in HCC tissues and cells.
The RFC complex has been identified as an important component of the cell cycle (10) . The overexpression of the RFC complex was has been found to be responsible for DNA replication, DNA damage repair, checkpoints and inducing tumor formation (7, 10, 12, 25) . Previous studies have demonstrated that RFC subunits are upregulated in different types of malignancies: RFC2, RFC3, RFC4 and RFC5 are upregulated in nasopharyngeal (13) , ovarian (12) , HCC (26) and human papillomavirus-positive squamous cell carcinomas (27) , respectively. In agreement with these findings, we found that the expression of RFC3 was significantly upregulated in human HCC tissues and cell lines. Owing to the importance of RFC3 in the formation of DNA replication complex, it has been suggested that the overexpression of RFC3 is responsible for inducing tumor formation (13) . Based on this hypothesis, RFC3 can be identified as one of the most important cancer antigens.
After noting that RCF3 was associated with HCC, we focused on whether the downregulation of RFC3 affects HCC cells. Lentivirus-mediated RNAi methods provide an attractive approach to efficiently suppress gene expression. The RNAi knockdown assays revealed that the suppression of RFC3 expression in HCC cells led to a considerable suppression of HCC cell viability and proliferation. These results are consistent with those of a previous study which demonstrated that RFC3 was overexpressed in esophageal adenocarcinoma and that RFC3 knockdown had an anti-proliferative effect (13) . This suppression may be partly due to the induction of cancer cell cycle arrest at the S phase, the checkpoint of which is activated upon the formation and function of DNA replication complexes (28, 29) . Given that RFC3 is one of the key components of DNA replication complexes, the downregulation of RFC3 is likely to result in the blockade of DNA replication complex formation and eventually suppress DNA replication.
The knockdown of RFC3 increased the levels of S phaseassociated proteins, such as p21, p53 and p57, but reduced the expression of cyclin A. In the cell cycle, the CDK2/cyclin A complex leads to progression through the G1-S phase transition, a step that is strictly regulated in the process of cell proliferation. p21 and p51, CDK inhibitors, bind to CDK2 and inhibit its activity. The overexpression of p21 and/or p51 results in cells remaining in the G1/S phase and the arrest of cell cycle progression. p53 is known to be an activator of p21 expression (20) . It was proposed herein that the knockdown of RFC3 upregulates p53 expression, and subsequently induces p21 and/or p51 upregulation, and eventually inhibits G1-S phase transition. Further studies are required however, to focus on the detailed mechanisms behind the RFC3 regulation of cell cycle-related proteins.
In conclusion, the present study demonstrated that RFC3 was notably upregulated in HCC tissues and cell lines. The downregulation of RFC3 suppressed HCC cell viability and proliferation. Further experiments demonstrated that the knockdown of RFC3 induced HCC cell cycle arrest at the S phase. Tumor suppression was likely accomplished partially by inducing S phase arrest and regulating cell cycle-related proteins. These results indicate that RFC3 plays an important role in the development of HCC. Therefore, we suggest that a specific enzymatic inhibitor to RFC3 may have therapeutic significance in the treatment of HCC.
